Navigation Links
Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer
Date:9/10/2009

BATON ROUGE, La., Sept. 10 /PRNewswire/ -- Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over-expressed in a wide range of cancers including breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090421/NE02455LOGO )

"We are pleased to have begun human clinical trials of EP-100 as a novel cancer therapeutic candidate with the potential to offer an improved safety and efficacy profile over existing therapies such as radiation or chemotherapy," said Hector Alila, Ph.D., President of Esperance. "Preclinical studies of EP-100 demonstrated this candidate's efficacy across multiple indications in oncology, including aggressive cancers known to be resistant to the current standards of care and, importantly, studies of EP-100's mechanism-of-action support that it targets and selectively kills cancer cells without harming normal cells."

The Phase 1 study is a multi-center, open-label, dose escalating study designed to evaluate the safety, pharmacodynamic and pharmacokinetic properties of EP-100. This study will enroll adult patients with solid tumors that over-express LHRH receptors as determined by tumor biopsy. Up to a total of 36 patients that are either refractory to the standard of care or for which no standard of care exists may be enrolled in the study. EP-
'/>"/>

SOURCE Esperance Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...TOCKHOLM, November 20 Karolinska D...vestment Fund (EIF) has entered into a,co-investme...und will be,managed by Karolinska Development and ...-stage pharmaceutical and medical technology compa... co-investment fund. The agreement,represents EIF,...
(Date:11/19/2009)..., Nov. 19 Danish Prince Joachim in...thanol plant in Kalundborg, Denmark, on Wednesday,...irst and largest 2nd generation ethanol demonstrat...are used in the plant,s innovative process for con...isco, was the first to market with commercial enzy...
(Date:11/19/2009)... Md., Nov. 19 Spherix In...chnology for diabetes therapy, and a provider of t...d, supplement, biotechnology and pharmaceutical co...Annual Meeting of Shareholders. ,, At the meeti... SPEX ) elected the following members to the Board...
(Date:11/19/2009)... World,s Top Gene Synthesis Companies Form In...ordinate Best Practices in Risk Reduction ,Five ... Gene Synthesis Capacity , ...squo;s leading gene synthesis companies today anno...ening protocol to promote biosecurity in the gene ...
Breaking Biology Technology:Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 3DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4
..., April 9 /PRNewswire-FirstCall/ - OncoGenex Pharm...ASDAQ: OGXI ), announced today that it has been ...y LifeSciences British Columbia. This annual award...recognize a local organization that has made outst... Columbia,s life sciences industry. This award rec...
... Cell Biosciences, a provider of nanoproteomic an...announced the closing of a $10 million Series C fi...me Trust. Existing investors Domain Associates, L...es, Royal Bank of Canada and The Vertical Group al...y happy to announce this financing in the current ...
... 9 Cepheid (Nasdaq: CPHD ) today announced that...irst quarter ended March 31, 2009, on Thursday, Ap...The company will host a management presentation at...to discuss the results. To access the live webcas....com/investors at least 15 minutes before the sc...
Other Biology Technology:OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia 2OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia 3Cell Biosciences Closes $10 Million Series C Financing 2Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast 2
(Date:11/20/2009)...vember 19, 2009 The estimated 4.6 million America...of developing respiratory symptoms due to poor air...ire study undertaken earlier this year by investig...erinary Medicine. , The studywhich polled more t... percent of individuals working in barns complaine...
(Date:11/20/2009)...le in German . , In the current online issu...Stefanie Eyerich and Dr. Kilian Eyerich together w...and Istituto Dermopatico dell,Immacolata in Rome, ...nts a milestone on the way to developing new treat...s psoriasis and allergic reactions and potentially...
(Date:11/20/2009)...w study, researchers report that a class of heart ...l, or harmful, effect on the heart, depending on t...ars in the journal Circulation Research , found t...beta-receptors on the heart muscle offer the most ...et only the beta-receptors can actually undermine ...
Breaking Biology News(10 mins):Barn personnel experience higher-than-average rates of respiratory symptoms 2Discovery of new type of immune cells regulating inflammation in chronic diseases 2Carvedilol shown to have unique characteristics among beta blockers 2Scientists identify gene vital to early embryonic cells forming a normal heart and skull 12703 1Scientists identify gene vital to early embryonic cells forming a normal heart and skull 12703 2Norway Japan prop up whaling industry with taxpayer money 8913 1Norway Japan prop up whaling industry with taxpayer money 8913 2Burner Balm Joins Forces With Call to the Wall 49440 1
...sons are the Clark Kents of a genome. Apparently m...ursts of activity, these free-floating bits of gen...king into the genetic maps of plants and animals, ...ars, researchers thought that most of this DNA was...ings, however, are peeling back the odd and baffli...
... i.e. substances which can be stimulated to emit ...research and medical diagnosis. Fluorescence can b...expression of genes, to locate proteins in cells a...udy the location and migration of cells. Of partic... imaging with novel techniques that allow tomograp...
...ldstein checks his lobster traps in New Hampshire,... crustaceans to sell. Instead, the University of N...ters with transmitters and tracking their migratio... along the New Hampshire coastline and into Great ...funded by N.H. Sea Grant, will provide more accura...
Other Biology News:New research shows how gene function drives natural selection in important class of genetic elements 2New research shows how gene function drives natural selection in important class of genetic elements 3Novel technique for fluorescence tomography of tumors in living animals 2UNH researchers track lobster migrations to improve population estimates 2UNH researchers track lobster migrations to improve population estimates 3
...us venom Description: Phosphodiesterase I (venom e...d structure and sequence (1) . It hydrolyzes 5'-mo...onucleotides and deoxyribo-oligonucleotides (2) . ...ns at the pyrophosphate linkages to yield phosphor...
Spacer for Miniature FRENCH Pressure Cell from Thermo Scientific
...criptase is a recombinant Moloney murine leukemia ... Reverse Transcriptase is similar to MuLV reverse .... MuLV reverse transcriptase is a recombinant RNA-... RNA as a template in the presence of a primer to ...
...to Prostaglandin F2α (8-iso-13,14-dihydro-1...stane, 8-isoprostane (8-iso PGF2α), in rabb...G-like product of non-specific lipid peroxidation....-isoprostane is converted primarily to metabolites...
Biology Products: